Correction to: *Scientific Reports* 10.1038/s41598-018-19592-8, published online 19 January 2018

This Article contains an error in Figure 1 where panels C and D are reversed. The correct Figure 1 appears below as Figure [1](#Fig1){ref-type="fig"}.Figure 1Retinal histology (*upper panels*, *A*--*D*) and quantitative morphometric analysis of ONL thickness (*lower panels*, *E*--*G*) of control *vs*. AY9944-treated rats on various diets. Light microscopy images (resin embedment, Toluidine blue stain; 40X objective) at age PN 80 days, under the following conditions: (**A**) Untreated rat fed a standard rodent diet (C1 group; *black*); (**B**) AY9944-treated rat fed a CHOL-free rodent diet (AY1 group; *red*); (**C**) AY9944-treated rat fed high-CHOL diet (AY2 group; *blue*); and (**D**) AY9944-treated rat fed high-CHOL diet supplemented with antioxidants (AY3 group; *green*). Presumed phagosomes in RPE are denoted by white arrows. *Abbreviations*: RPE, retinal pigment epithelium; OS, outer segment layer; IS, inner segment layer; ONL, outer nuclear layer; INL, inner nuclear layer. Scale bar (*panel* A, for all panels), 20 μm. ONL thickness measurements from (**E**) superior hemisphere, (**F**) inferior hemisphere, and (**G**) combined mean values (both hemispheres, ±S.E.M.; n = 3--4 biological replicates, n = 10 technical replicates, each condition), along the vertical meridian. Statistical significance (one-way ANOVA): \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.005, \*\*\*\**p* \< 0.001; n.s., not significant.

Additionally, this Article contains errors in the Methods section under subheading 'Lipid extraction and UHPLC-MS/MS analyses of sterols and oxysterols'.

"Analysis of sterols and oxysterols were performed by UHPLC-MS/MS using a triple-quadrupole mass spectrometer (API 4000^TM^ or 6500^TM^; AB SCIEX, Ontario, Canada) equipped with atmospheric pressure chemical ionization (APCI)."

should read:

"Analysis of sterols and oxysterols were performed by UHPLC-MS/MS using a triple-quadrupole mass spectrometer (API 4000™ or 6500™ (for retina and serum oxysterols only); AB SCIEX, Ontario, Canada) equipped with atmospheric pressure chemical ionization (APCI)."

"MS conditions: spray voltage, 5000 V; curtain gas, 10 psi; ion source gas, 20 psi; collision gas, high; entrance potential, 10 V; collision energy, 25 V; declustering potential, 80.00 V; temperature, 300 °C."

should read:

"MS conditions: declustering potential, 80 V; entrance potential, 10 V; collision energy, 25 V; collision cell exit potential, 20.0 V. APCI parameters: nebulizer current, 3 mA; temperature, 300 °C; curtain gas, 10 psi for 4000™ and 20 psi for 6500™; ion source gas, 20 psi for 4000™and 55 psi for 6500™."

Finally, the Acknowledgements section in this Article is incomplete.
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should read:

"This work was supported, in part: by U.S.P.H.S. (NIH) grants R01 EY007361 (SJF), R00 HD073270 (LX), and R01 HD092659 (LX); by Clinical and Translational Science Award UL1 TR001412 to the University at Buffalo-The State University of New York from NCATS/NIH (SJF); by a Foundation Fighting Blindness Center Grant (an unrestricted award) to the Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (NSP); by Research to Prevent Blindness Unrestricted Grants to the Departments of Ophthalmology, University at Buffalo-The State University of New York and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University from Research to Prevent Blindness (SJF, NSP); by startup funds from the Department of Medicinal Chemistry, School of Pharmacy, University of Washington (LX); and by facilities and resources provided by the VA Western New York Healthcare System (SJF) and the Louis Stokes Cleveland VA Medical Center (NSP)."

The original article can be found online at 10.1038/s41598-018-19592-8.
